14 Stocks on Jim Cramer’s Radar

5. Abbott Laboratories (NYSE:ABT)

Number of Hedge Fund Holdings: 68

Pharma giant Abbott Laboratories (NYSE:ABT)’s shares are down 15.9% over the past year and 12% year-to-date. The stock was dealt a hefty blow in January after the firm reported its fiscal fourth quarter earnings. The results saw Abbott Laboratories (NYSE:ABT) post $11.46 billion in revenue and $1.50 in profit per share. The revenue missed analyst estimates of $11.80 billion, while the profit met the estimates. Additionally, Abbott Laboratories (NYSE:ABT)’s first-quarter profit guidance of $1.12 and $1.18 missed analyst estimates of $1.20. Following the earnings, Evercore ISI cut the firm’s share price target to $138 from $144 and kept an Outperform rating. In its coverage, the financial firm noted that while Abbott Laboratories (NYSE:ABT)’s had missed its quarterly estimates, the firm’s long-term picture nevertheless remained robust. Cramer, like Evercore, also kept an upbeat tone about the stock:

“This is a high-quality company. One of the greatest known for a very long time. Diagnostics they’re great, nutrition, medical devices. They did come through with what I regard as being, they don’t want to regard penicillin as a shortfall. I don’t to blame them because it’s very tough in terms of their growth. But did say, they’re not gonna make the numbers next quarter. And David, what bothers me, nutrition’s been weak, but it’s diagnostics, Abbott is the world’s best diagnostic company. So they’re not going to be able to do their number, it’s not clear exactly why, I don’t like that. They are the, the Exact Sciences. . .deal is on track. But this is the one, that I think, it’s really the only big cap pharma drug that’s disappointed. And I’m trying to figure out whether this is a buying opportunity, I think Robert Ford does a good job. . .”

Parnassus Value Equity Fund also discussed Abbott Laboratories (NYSE:ABT) in its third quarter 2025 investor letter:

“Abbott Laboratories (NYSE:ABT) stands out for its durable growth potential driven by steady demand in areas like diabetes care, heart health and electrophysiology, all supported by ongoing innovation and new product launches. We also believe Abbott’s diversified business model, global reach and leadership positions in key markets can provide resilient returns for long-term investors.”